Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders.

Autor: Omwandho CO; Department of Biochemistry, University of Nairobi, Nairobi, Kenya., Gruessner SE, Roberts TK, Tinneberg HR
Jazyk: angličtina
Zdroj: Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2004 Apr; Vol. 42 (4), pp. 359-70.
DOI: 10.1515/CCLM.2004.065
Abstrakt: Recurrent pregnancy loss has been associated with autoimmune responses to membrane phospholipids and alloimmune reactions against paternally derived molecules on the trophoblast. The problem is psychologically and economically stressful as it undermines the capacity of some couples to reproduce and participate effectively in the day-to-day economic activities. This article reviews the adoption of intravenous immunoglobulin as a form of therapy for the clinical management of recurrent pregnancy loss and of selected autoimmune disorders. Side effects, contraindications and safety of use are discussed.
Databáze: MEDLINE